Direct oral anticoagulants continue to be underutilized and inappropriately dosed. The American College of Cardiology hopes a new scientific statement can help address those issues and provide clinicians with an updated look at this important topic.

The updated labeling comes after the devices were found to be both safe and effective for the treatment of ruptured aneurysms. 

Today's sophisticated mapping systems allow clinicians to visualize VT circuits with unprecedented detail.

Patients were randomized to undergo treatment with the new-look AnchorMan or the Watchman 2.5. A follow-up study comparing the AnchorMan to the Watchman FLX and FLX Pro devices is already planned.

The same device was previously recalled back in 2022. Customers are urged to return any unused delivery systems included in the recall to Medtronic.

The daily polypill was also associated with improved drug adherence, according to new research out of UT Southwestern.

The company now has multiple FDA-cleared algorithms for evaluating CCTA results.

The FDA-cleared ShortCut leaflet modification device has been linked to positive real-world outcomes.

These "forward-thinking organizations" have all committed to participating in multiple data registries and quality improvement programs. Did your facility make the cut? 

The procedure is designed to help patients who experience frequent fainting episodes that impair their quality of life.